A press release made yesterday brought some bad news to the advanced prostate cancer community. Takeda Pharmaceutical Company Limited (“Takeda”) announced that it has un-blinded and stopped the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed [...]
Many men, after they have had a radical prostatectomy, find that their testosterone levels are low and are desirous of supplementing their testosterone. (This low level of testosterone is not a result of the surgery). One way of supplementing androgens is by transdermal testosterone-replacement therapy (TRT), but TRT also has the undesirable effect of increasing [...]
Conversations among survivors and evidence in the literature suggests that there is a positive association between serum 25-hydroxyvitamin D [25(OH)D] (vitamin D3) and survival in certain types of cancer, including advanced prostate cancer. Researchers from the Cancer Treatment Centers of America investigated the relationship between survival advantage and vitamin D3 levels in [...]
Xtandi is often referred to as a “super bicalutamide (Casodex).” Casodex functions as a androgen blockade, which deters testosterone from being able to interact with the prostate cancer cell and feed the growth of the cancer. There are some oncologists in the United States and the standard hormone treatment in Europe often utilizes Casodex as [...]
The recent news is unavoidable, Omega-3 Fatty Acids, usually used by men with heart ailments and prostate cancer is tied to a 71% increase of developing prostate cancer and that the cancer is often an aggressive prostate cancer! A prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high [...]
Why does PSA continue to rise and prostate cancer disease continue to progress (new tumors develop and existing tumors continue to get bigger) when a man has an immune system treatment to go after their prostate cancer? This issue is probably the major marketing hurdle faced by Dendreon’s Provenge and based on the current statistics [...]
Many of us believe that prostate cancer is one specific disease, however this is not true. In fact we now know that there are at least twenty-three different types off prostate cancer. The most common types of prostate cancer, or ninety-five percent of them are referred to as adenocarcinomas. One of the least common types [...]
There have been many potential targets identified for the treatment of advanced prostate cancer. Many of these targets are being actively explored with clinical trials designed to test some inhibitors of the targets. Antisense oligonucleotides (OGX-011) targets clusterin, a chaperone protein and OGX-427 which targets heat-shock protein 27 are among the inhibitors being evaluated. OGX-011 [...]
Osteoblasts and osteoclasts are the process that the body uses to breakdown old bone and then to rebuild it with new bone. c-Met is a tyrosine kinase expressed by osteoblasts and osteoclasts, and overexpressed by prostate cancer cells. This over expression leads to the eventual development of bone metastases. The experimental treatment known as Cabozantinib [...]
Since it FDA approval in 2004, docetaxel (a taxane based chemotherapy) has been the standard first-line chemotherapy for men with metastatic prostate cancer (mCRPC). Other than the trial of Provenge all the successful phase III trials conducted in mCRPC focused on men experiencing cancer progression after first-line docetaxel chemotherapy. The implication is that improving the [...]
